- Trials with a EudraCT protocol (66)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
66 result(s) found for: IFN-gamma.
Displaying page 2 of 4.
| EudraCT Number: 2020-002312-43 | Sponsor Protocol Number: 01052020 | Start Date*: 2020-05-28 |
| Sponsor Name:Miguel Cervero Jiménez, servicio de Medicina Interna, Hospital Universitario Severo Ochoa | ||
| Full Title: Clinical trial, PHASE III, randomized, open-label, to evaluate the efficacy of administering high-dose cholecalciferol orally alongside standard therapy in patients with COVID-19 pneumonia (COVID-1... | ||
| Medical condition: COVID-19 PNEUMONIA | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-001928-37 | Sponsor Protocol Number: 104540 | Start Date*: 2005-09-13 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate vaccine containing the adjuvant AS25 (FluAS25)... | ||
| Medical condition: Immunisation against influenza disease in elderly population aged over 65 years (>65 years) | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-003303-18 | Sponsor Protocol Number: rl.01.2013 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Gedeon Richter Polska Sp. z o. o. | ||
| Full Title: Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnose... | ||
| Medical condition: Recurrent airway inflammation in children with impaired cellular immunity. | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: PL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-000784-33 | Sponsor Protocol Number: TacTremorConversion | Start Date*: 2017-07-31 | |||||||||||
| Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | |||||||||||||
| Full Title: Effect of Envarsus conversion on tacrolimus-associated tremor in renal transplant patients. An open-label, single centre, prospective pharmacodynamic/pharmacokinetic clinical study | |||||||||||||
| Medical condition: Tacrolimus-associated tremor | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002032-69 | Sponsor Protocol Number: COVITOZ-01 | Start Date*: 2020-05-04 | |||||||||||
| Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | |||||||||||||
| Full Title: Single-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 | |||||||||||||
| Medical condition: Non-severe pneumonia caused by COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-004799-50 | Sponsor Protocol Number: PNEUMOREG | Start Date*: 2015-02-13 |
| Sponsor Name:Federico Martinon Torres | ||
| Full Title: Evaluation of the immunoregulatory role of pneumococcal conjugate vaccination in pediatric patients with allergic asthma or type 1 diabetes mellitus versus pediatric population control. | ||
| Medical condition: Allergic asthma and type 1 diabetes mellitus in pediatric subjects. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-003023-20 | Sponsor Protocol Number: UCL-PLTP-002 | Start Date*: 2008-09-11 | |||||||||||
| Sponsor Name:Cliniques universitaires Saint-Luc | |||||||||||||
| Full Title: TACROLIMUS – DACLIZUMAB - MYCOPHENOLATE MOFETIL IMMUNE PROPHYLAXIS IN PEDIATRIC LIVER TRANSPLANTATION. An open, pilot, investigator-driven study in 20 recipients | |||||||||||||
| Medical condition: Liver transplantation | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-022248-19 | Sponsor Protocol Number: 114825 | Start Date*: 2011-01-25 | |||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
| Full Title: An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... | |||||||||||||
| Medical condition: Evaluation of persistence of immune responses following immunisation of healthy elderly subjects (60-69 and ≥70 years) against Herpes Zoster (HZ) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DE (Completed) NL (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000411-91 | Sponsor Protocol Number: NKZellen-Version1.0 | Start Date*: 2013-02-13 |
| Sponsor Name:Charité - Universitätsmedizin Berlin | ||
| Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial | ||
| Medical condition: relapsing-remitting multiple sclerosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-001167-93 | Sponsor Protocol Number: Sobi.IMMUNO-101 | Start Date*: 2020-03-27 | |||||||||||
| Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL) | |||||||||||||
| Full Title: A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFN¿... | |||||||||||||
| Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001892-34 | Sponsor Protocol Number: PI20208430041 | Start Date*: 2020-06-20 |
| Sponsor Name:CHU Amiens-Picardie | ||
| Full Title: Treatment of COVID-19 by Nebulization of Inteferon Beta 1b added to lopinavir/ritonavir: Feasibility, Efficiency and Safety Study | ||
| Medical condition: Infection SARS-Cov-2 | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-000988-68 | Sponsor Protocol Number: O2021-1 | Start Date*: 2021-03-31 |
| Sponsor Name: Region Stockholm | ||
| Full Title: Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 . | ||
| Medical condition: Renal failure stage 4 and 5. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-005150-28 | Sponsor Protocol Number: PTC:VS-TC | Start Date*: 2022-07-25 | |||||||||||
| Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
| Full Title: Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation(HSCT) | |||||||||||||
| Medical condition: Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-005210-22 | Sponsor Protocol Number: BOOG-2017-02 | Start Date*: 2018-04-25 | |||||||||||
| Sponsor Name:BOOG Study Center | |||||||||||||
| Full Title: Explorative trial to identify the impact of denosumab on the systemic immunity and local immunologic microenvironment in postmenopausal patients with HER2 negative breast cancer. | |||||||||||||
| Medical condition: Mamma carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-014600-66 | Sponsor Protocol Number: IFN-gamma 001 | Start Date*: 2010-08-10 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:University Medical Center Nijmegen | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A multicentre, prospective, randomized open-label pilot study to assess the feasibility and preliminary efficacy of interferon gamma in combination with Anidulafungin for the treatment of candidemia | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Candida bloodstream infections/ candidemia | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-000064-21 | Sponsor Protocol Number: TPN-101-AGS-201 | Start Date*: 2022-09-20 | |||||||||||
| Sponsor Name:Transposon Therapeutics Inc | |||||||||||||
| Full Title: A Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS) | |||||||||||||
| Medical condition: Aicardi-Goutières Syndrome (AGS) | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-017296-17 | Sponsor Protocol Number: TESEC-03 | Start Date*: 2011-04-04 | |||||||||||
| Sponsor Name:Statens Serum Institut | |||||||||||||
| Full Title: A phase IIa specificity trial of the diagnostic agent C-Tb, when given intradermally by the Mantoux technique to healthy volunteers previously vaccinated with BCG | |||||||||||||
| Medical condition: The intended indication for the product is to be a diagnostic tool to detect infection with M.tuberculosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-001914-41 | Sponsor Protocol Number: AL1201AV | Start Date*: 2012-10-19 | ||||||||||||||||
| Sponsor Name:Allergopharma Joachim Ganzer KG | ||||||||||||||||||
| Full Title: Open label phase II multicentre clinical trial to evaluate safety during shortened uptitration of an allergoid grass pollen preparation in adult patients with IgE mediated allergic rhinitis / rhino... | ||||||||||||||||||
| Medical condition: ICD classificationcode: J 45.0 and J30.1 Patients with IgE mediated allergic rhinitis / rhinoconjunctivitis with or without controlled bronchial asthma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-003188-31 | Sponsor Protocol Number: INF-V-A007 | Start Date*: 2011-10-24 | |||||||||||
| Sponsor Name:CRUCELL SWITZERLAND AG | |||||||||||||
| Full Title: A Phase IV, open label study to evaluate the immune response against homogenous and heterogenous circulating strains in elderly subjects after vaccination with Inflexal V | |||||||||||||
| Medical condition: Healthy female and male elderly subjects where influenza vaccination is suggested | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-002901-33 | Sponsor Protocol Number: CVC-201 | Start Date*: 2007-08-10 | |||||||||||
| Sponsor Name:Tripep AB | |||||||||||||
| Full Title: A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered ChronVac-C® in Combination with Electroporation in Chronic Hepatitis C Virus Genotype ... | |||||||||||||
| Medical condition: Treatment of chronic infections caused by hepatitis C virus genotype 1 strains | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.